Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Glaxo Wellcome
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must have:
A positive HIV antibody test (ELISA confirmed by Western blot).
Chronic renal failure managed by a stable hemodialysis regimen.
Acceptable hepatic function defined by specified lab values.
Life expectancy \> 6 months.
Enrollment is limited to 9 chronic hemodialysis patients and 9 Continuous Ambulatory Peritoneal Dialysis (CAPD) patients. These patients must be stable in their ESRD treatment regimen before entry.
You may not be if
Co-existing Condition:
Patients with the following are excluded:
Active, serious opportunistic infections at the time of study entry.
Fever \> 100 degrees F at study entry.
Severe malabsorption (evidenced by persistent diarrhea of greater than 4 weeks duration with = or \> 6 loose stools per day accompanied by significant weight loss).
Patients with the following are excluded:
Active, serious opportunistic infections at the time of study entry.
Fever \> 100 degrees F at study entry.
Severe malabsorption (evidenced by persistent diarrhea of greater than 4 weeks duration with = or \> 6 loose stools per day accompanied by significant weight loss).
Prior Medication:
Excluded within 2 weeks of study entry:
\- Any other experimental therapy. Drugs which cause significant bone marrow suppression. Rifampin or rifampin derivatives. Cytolytic chemotherapy. Drugs which cause significant hepatotoxicity.
Excluded within 4 weeks of study entry:
\- Immunomodulating agents, including steroids, interferon, Isoprinosine, and interleukin 2.
Excluded within 8 weeks of study entry:
\- Other antiretroviral agents (e.g., zidovudine \[AZT\], suramin, ribavirin, HPA-23, foscarnet, dextran sulfate, disulfiram, ddA/ddC, or dideoxycytidine).
